Analysis of therapies for chronic plaque psoriasis in HIV-positive individuals, highlighting the impact of ART on immune function and management issues.
Psoriasis and other chronic inflammatory skin diseases present unique therapeutic challenges in people living with HIV (PLHIV). Historically, concerns regarding immunosuppression and the risk of opportunistic infection have limited the use of systemic and biologic therapies in this population. Although the advent of effective antiretroviral therapy (ART) has markedly improved immune function and life expectancy, robust evidence guiding the management of moderate-to-severe psoriasis in PLHIV remains scarce.
No takes yet. Share an insight, caveat, or question.
Rooij et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: